Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger

Acta Tropica

Volumn 128, Issue 2, 2013, Pages 334-344

  Garba, Amadou ^a,b,c   Lamine, Mariama S ^a   Barkiré, Nouhou ^d   Djibo, Ali ^d   Sofo, Boubacar ^a   Gouvras, Anouk N ^e   Labbo, Rabiou ^a,f   Sebangou, Hannatou ^a   Webster, Joanne P ^e   Fenwick, Alan ^e   Utzinger, Jürg ^b,c  

^a Aménagement et Lutte ^*  (Niger)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITÉ ABDOU MOUMOUNI   (Niger)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Centre de Recherche Médicale et Sanitaire   (Niger)

Author keywords

Efficacy; Mixed infection; Niger; Praziquantel; Re infection pattern; Safety; Schistosoma haematobium; Schistosoma mansoni; Schistosomiasis; School aged children

Indexed keywords

PRAZIQUANTEL;

CHILD HEALTH; COHORT ANALYSIS; DISEASE PREVALENCE; DISEASE TREATMENT; INFECTIVITY; PARASITE; PARASITOLOGY; SAFETY; VILLAGE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGERIA; PARASITE IDENTIFICATION; PATIENT MONITORING; PRESCHOOL CHILD; PREVALENCE; PRURITUS; QUESTIONNAIRE; RASH; REINFECTION; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; SOMNOLENCE; TREATMENT OUTCOME; URINALYSIS; VOMITING;

NIGER [NIGERIA]; NIGERIA;

SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI;

EFFICACY; MIXED INFECTION; NIGER; PRAZIQUANTEL; RE-INFECTION PATTERN; SAFETY; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHOOL-AGED CHILDREN;

ADOLESCENT; ANIMALS; ANTHELMINTICS; CHILD; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; NIGER; PRAZIQUANTEL; PREVALENCE; RECURRENCE; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; STUDENTS; TREATMENT OUTCOME;

EID: 84885483817     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2012.08.008     Document Type: Article

References (61)

1. Berhe N., Gundersen S.G., Abebe F., Birrie H., Medhin G., Gemetchu T. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop. 1999, 72:53-63.
2. Brady M.A., Hooper P.J., Ottesen E.A. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol. 2006, 22:285-291.
3. Daffalla A.A., Fenwick A. Resurgence of Schistosoma mansoni and Schistosoma haematobium after the end of a 4-year control programme against S. mansoni. Trans. R Soc. Trop. Med. Hyg. 1982, 76:701-702.
4. Danso-Appiah A., Garner P., Olliaro P.L., Utzinger J. Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review. Parasitology 2009, 136:1837-1849.
5. Dembélé M., Bamani S., Dembélé R., Traoré M.O., Goita S., Traoré M.N., Sidibe A.K., Sam L., Tuinsma M., Toubali E., Macarthur C., Baker S.K., Zhang Y. Implementing preventive chemotherapy through an integrated national neglected tropical disease control program in Mali. PLoS Negl. Trop. Dis. 2012, 6:e1574.
6. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 2008, 21:659-667.
7. Ernould J.C., Garba A., Labbo R., Kaman A.K., Sidiki A., Djibrilla A., Chippaux J.P. Hétérogénéité de la transmission de Schistosoma haematobium dans les périmètres irrigués du Niger. Bull. Soc. Pathol. Exot. 2004, 97:19-23.
8. Fleming F.M., Fenwick A., Tukahebwa E.M., Lubanga R.G., Namwangye H., Zaramba S., Kabatereine N.B. Process evaluation of schistosomiasis control in Uganda, 2003 to 2006: perceptions, attitudes and constraints of a national programme. Parasitology 2009, 136:1759-1769.
9. Garba A., Barkire N., Djibo A., Lamine M.S., Sofo B., Gouvras A.N., Bosque-Oliva E., Webster J.P., Stothard J.R., Utzinger J., Fenwick A. Schistosomiasis in infants and preschool-aged children: infection in a single Schistosoma haematobium and a mixed S. haematobium-S. mansoni foci of Niger. Acta Trop. 2010, 115:212-219.
10. Garba A., Labbo R., Tohon Z., Sidiki A., Djibrilla A. Emergence of Schistosoma mansoni in the Niger River valley, Niger. Trans. R Soc. Trop. Med. Hyg. 2004, 98:296-298.
11. Garba A., Tohon Z., Sidiki A., Chippaux J.P., de Chabalier F. Efficacité et tolérance du praziquantel chez l'enfant d'âge scolarire en zone hyper-endémique à Schistosoma haematobium (Niger, 1999). Bull. Soc. Pathol. Exot. 2001, 94:42-45.
12. Gouvras A.N., Kariuki C., Koukounari A., Lange N.C., Norton A., Ireri E., Fenwick A., Mkoji M.G., Webster J.P. Morbidity of mixed versus single infections of Schistosoma mansoni and S. haematobium at baseline and 12 months after praziquantel administration in Taveta. Kenya. Acta Trop. 2013, 128:309-317.
13. Gryseels B. Schistosomiasis. Infect. Dis. Clin. North Am. 2012, 26:383-397.
14. Gryseels B., Mbaye A., De Vlas S.J., Stelma F.F., Guisse F., Van Lieshout L., Faye D., Diop M., Ly A., Tchuem Tchuenté L.A., Engels D., Polman K. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health 2001, 6:864-873.
15. Hotez P.J., Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis. 2009, 3:e412.
16. Hotez P.J., Pecoul B. Manifesto for advancing the control and elimination of neglected tropical diseases. PLoS Negl. Trop. Dis. 2010, 4:e718.
17. Hotez P.J., Engels D., Fenwick A., Savioli L. Africa is desperate for praziquantel. Lancet 2010, 376:496-498.
18. Hotez P.J., Fenwick A., Kjetland E.F. Africa's 32 cents solution for HIV/AIDS. PLoS Negl. Trop. Dis. 2009, 3:e430.
19. Hotez P.J., Molyneux D.H., Fenwick A., Ottesen E., Ehrlich Sachs S., Sachs J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006, 3:e102.
20. Inyang-Etoh P.C., Ejezie G.C., Useh M.F., Inyang-Etoh E.C. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans. R Soc. Trop. Med. Hyg. 2009, 103:38-44.
21. Kabatereine N.B., Kemijumbi J., Ouma J.H., Sturrock R.F., Butterworth A.E., Madsen H., Ørnbjerg N., Dunne D.W., Vennnervald B.J. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans. R Soc. Trop. Med. Hyg. 2003, 97:599-603.
22. Kabatereine N.B., Malecela M., Lado M., Zaramba S., Amiel O., Kolaczinski J.H. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa. PLoS Negl. Trop. Dis. 2010, 4:e755.
23. Kahama A.I., Vennervald B.J., Kombe Y., Kihara R.W., Ndzovu M., Mungai P., Ouma J.H. Parameters associated with Schistosoma haematobium infection before and after chemotherapy in school children from two villages in the coast province of Kenya. Trop. Med. Int. Health 1999, 4:335-340.
24. Katz N., Chaves A., Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev. Inst. Med. Trop. Sâo Paulo 1972, 14:397-400.
25. Keiser J., N'Guessan N.A., Adoubryn K.D., Silué K.D., Vounatsou P., Hatz C., Utzinger J., N'Goran E.K. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin. Infect. Dis. 2010, 50:1205-1213.
26. King C.H., Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008, 4:65-79.
27. King C.H., Olbrych S.K., Soon M., Singer M.E., Carter J., Colley D.G. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl. Trop. Dis. 2011, 5:e1321.
28. Kolaczinski J.H., Kabatereine N.B., Onapa A.W., Ndyomugyenyi R., Kakembo A.S., Brooker S. Neglected tropical diseases in Uganda: the prospect and challenge of integrated control. Trends Parasitol. 2007, 23:485-493.
29. Labbo R., Ernould J.C., Djibrilla A., Garba A., Chippaux J.P. Focalisation de la transmission de Schistosoma haematobium au sein des périmètres irrigués de la vallée du Niger (Niger): importance des facteurs malacologiques. Rev. Epidémiol. Santé Publique. 2008, 56:3-9.
30. Labbo R., Garba A., Louboutin-Croc J.P., Ernould J.C., Sellin B., Chippaux J.P., Stothard J.R. The spread of Biomphalaria pfeifferi in the Niger River valley, Niger. Ann. Trop. Med. Parasitol. 2003, 97:209-212.
31. Lammie P.J., Fenwick A., Utzinger J. A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol. 2006, 22:313-321.
32. Lovis L., Mak T.K., Phongluxa K., Ayé Soukhathammavong P., Vonghachack Y., Keiser J., Vounatsou P., Tanner M., Hatz C., Utzinger J., Odermatt P., Akkhavong K. Efficacy of praziquantel against Schistosoma mekongi and Opisthorchis viverrini: a randomized, single-blinded dose-comparison trial. PLoS Negl. Trop. Dis. 2012, 6:e1726.
33. Midzi N., Sangweme D., Zinyowera S., Mapingure M.P., Brouwer K.C., Kumar N., Mutapi F., Woelk G., Mduluza T. Efficacy and side effects of praziquantel treatment against Schistosoma haematobium infection among primary school children in Zimbabwe. Trans. R Soc. Trop. Med. Hyg. 2008, 102:759-766.
34. Molyneux D.H., Hotez P.J., Fenwick A. Rapid-impact interventions: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2005, 2:e336.
35. N'Goran E.K., Gnaka H.N., Tanner M., Utzinger J. Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from CÔte d'Ivoire. Ann. Trop. Med. Parasitol. 2003, 97:37-51.
36. N'Goran E.K., Utzinger J., N'Guessan A.N., Müller I., Zamblé K., Lohourignon K.L., Traoré M., Sosthène B.A., Lengeler C., Tanner M. Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in CÔte d'Ivoire. Trop. Med. Int. Health 2001, 6:817-825.
37. Obonyo C.O., Muok E.M., Mwinzi P.N. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect. Dis. 2010, 10:603-611.
38. Olds G.R., King C., Hewlett J., Olveda R., Wu G., Ouma J., Peters P., McGarvey S., Odhiambo O., Koech D., Liu C.Y., Aligui G., Gachihi G., Kombe Y., Parraga I., Ramirez B., Whalen C., Horton R.J., Reeve P. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J. Infect. Dis. 1999, 179:996-1003.
39. Parker M., Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Res. Policy Syst. 2011, 9:3.
40. Parker M., Allen T., Hastings J. Resisting control of neglected tropical diseases: dilemmas in the mass treatment of schistosomiasis and soil-transmitted helminths in north-west Uganda. J. Biosoc. Sci. 2008, 40:161-181.
41. Picquet M., Vercruysse J., Shaw D.J., Diop M., Ly A. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans. R Soc. Trop. Med. Hyg. 1998, 92:90-93.
42. Raso G., N'Goran E.K., Toty A., Luginbühl A., Adjoua C.A., Tian-Bi N.T., Bogoch I.I., Vounatsou P., Tanner M., Utzinger J. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western CÔte d'Ivoire. Trans. R Soc. Trop. Med. Hyg. 2004, 98:18-27.
43. Sabah A.A., Fletcher C., Webbe G., Doenhoff M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 1986, 61:294-303.
44. Sacko M., Magnussen P., Traoré M., Landoure A., Doucoure A., Reimert C.M., Vennervald B.J. The effect of single dose versus two doses of praziquantel on Schistosoma haematobium infection and pathology among school-aged children in Mali. Parasitology 2009, 136:1851-1857.
45. Savioli L., Gabrielli A.F., Montresor A., Chitsulo L., Engels D. Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54.19. Parasitology 2009, 136:1677-1681.
46. Scherrer A.U., Sjöberg M.K., Allangba A., Traoré M., Lohourignon L.K., Tschannen A.B., N'Goran E.K., Utzinger J. Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. Acta Trop. 2009, 109:226-231.
47. Secor W.E. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr. Opin. HIV AIDS 2012, 7:254-259.
48. Sissoko M.S., Dabo A., Traoré H., Diallo M., Traoré B., Konaté D., Niaré B., Diakité M., Kamaté B., Traoré A., Bathily A., Tapily A., Touré O.B., Cauwenbergh S., Jansen H.F., Doumbo O.K. Efficacy of artesunate+sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 2009, 4:e6732.
49. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 2006, 6:411-425.
50. Tchuem Tchuenté L.A., Shaw D.J., Polla L., Cioli D., Vercruysse J. Efficacy of praziquantel against Schistosoma haematobium infection in children. Am. J. Trop. Med. Hyg. 2004, 71:778-782.
51. Tchuem Tchuenté L.A., Southgate V.R., Mbaye A., Engels D., Gryseels B. The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans. R Soc. Trop. Med. Hyg. 2001, 95:65-66.
52. Utzinger J., N'Goran E.K., Caffrey C.R., Keiser J. From innovation to application: social-ecological context, diagnostics and integrated control of schistosomiasis. Acta Trop. 2011, 120(Suppl. 1):S121-S137.
53. Utzinger J., N'Goran E.K., N'Dri A., Lengeler C., Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop. Med. Int. Health 2000, 5:771-778.
54. Utzinger J., Raso G., Brooker S., de Savigny D., Tanner M., Ørnbjerg N., Singer B.H., N'Goran E.K. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009, 136:1859-1874.
55. Utzinger J., Keiser J., Xiao S.H., Tanner M., Singer B.H. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob. Agents Chemother. 2003, 47:1487-1495.
56. WHO The control of schistosomiasis: report of a WHO expert committee. WHO Tech. Rep. Ser. 1985, 728:1-113.
57. WHO Report of the WHO Informal Consultation on Monitoring of Drug Efficacy in the Control of Schistosomiasis and Intestinal Nematodes 1998, World Health Organization, Geneva, pp. 1-45.
58. WHO Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech. Rep. Ser. 2002, 912:1-57.
59. WHO Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelmintic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers 2006, World Health Organization, Geneva, pp. 1-62.
60. WHO First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases 2010, World Health Organization, Geneva, WHO/HTM/NTD/2009.2, pp. 1-172.
61. WHO Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly. Epidemiol. Rec. 2012, 87:37-44.